Condition: Metastatic Solid Tumor · Advanced Solid Tumor · Sponsor: Coherus Oncology, Inc.
The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.
This description comes directly from the study's public registry record.
Clinical Operations Team · +1-800-794-5434 · clinicaltrials@coherus.com
Always discuss trial participation with your own doctor first.
| The University of Arizona Cancer Center | Tucson, Arizona, United States | Withdrawn |
| City of Hope | Duarte, California, United States | Recruiting |
| University of Colorado - Aurora Cancer Center | Aurora, Colorado, United States | Recruiting |
| Winship Cancer Center - Emory University | Atlanta, Georgia, United States | Recruiting |
| Ochsner Health | New Orleans, Louisiana, United States | Recruiting |
| Henry Ford Health System | Detroit, Michigan, United States | Recruiting |
| Comprehensive Cancer Center of Nevada | Las Vegas, Nevada, United States | Recruiting |
| Christus St Vincent Regional Medical Center | Santa Fe, New Mexico, United States | Recruiting |
| START New York | Lake Success, New York, United States | Recruiting |
| David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Icahn School of Medicine at Mount Sinai | New York, New York, United States | Recruiting |
| University of Pittsburg Medical Center _UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06657144